Oncolytics Biotech Inc (ONC) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Oncolytics Biotech Inc (ONC) has a cash flow conversion efficiency ratio of -0.899x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CA$-5.47 Million ≈ $-3.96 Million USD) by net assets (CA$6.09 Million ≈ $4.40 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See ONC net asset quality score to measure how much of total assets are equity-financed.
Oncolytics Biotech Inc - Cash Flow Conversion Efficiency Trend (1999–2024)
This chart illustrates how Oncolytics Biotech Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Oncolytics Biotech Inc earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.
Oncolytics Biotech Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Oncolytics Biotech Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Devsisters corporation
KQ:194480
|
0.052x |
|
Wellcall Holdings Bhd
KLSE:7231
|
0.003x |
|
Seoul City Gas
KO:017390
|
-0.022x |
|
Astra Graphia Tbk
JK:ASGR
|
0.006x |
|
Global Lighting Technologies Inc
TW:4935
|
0.006x |
|
Fiamma Holdings Bhd
KLSE:6939
|
-0.012x |
|
Butterfly Gandhimathi Appliances Limited
NSE:BUTTERFLY
|
0.033x |
|
Sam Young Chem
KO:003720
|
0.149x |
Annual Cash Flow Conversion Efficiency for Oncolytics Biotech Inc (1999–2024)
The table below shows the annual cash flow conversion efficiency of Oncolytics Biotech Inc from 1999 to 2024. For the full company profile with market capitalisation and key ratios, see Oncolytics Biotech Inc market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CA$5.98 Million ≈ $4.33 Million |
CA$-26.97 Million ≈ $-19.51 Million |
-4.507x | -336.69% |
| 2023-12-31 | CA$27.56 Million ≈ $19.94 Million |
CA$-28.45 Million ≈ $-20.58 Million |
-1.032x | -17.12% |
| 2022-12-31 | CA$26.50 Million ≈ $19.17 Million |
CA$-23.36 Million ≈ $-16.89 Million |
-0.881x | -41.80% |
| 2021-12-31 | CA$36.10 Million ≈ $26.11 Million |
CA$-22.43 Million ≈ $-16.23 Million |
-0.621x | +30.29% |
| 2020-12-31 | CA$24.75 Million ≈ $17.91 Million |
CA$-22.07 Million ≈ $-15.96 Million |
-0.892x | -100.48% |
| 2019-12-31 | CA$-107.89K ≈ $-78.05K |
CA$-19.91 Million ≈ $-14.40 Million |
184.497x | +9688.95% |
| 2018-12-31 | CA$6.20 Million ≈ $4.48 Million |
CA$-11.92 Million ≈ $-8.62 Million |
-1.924x | -7.03% |
| 2017-12-31 | CA$8.28 Million ≈ $5.99 Million |
CA$-14.89 Million ≈ $-10.77 Million |
-1.798x | -54.00% |
| 2016-12-31 | CA$10.69 Million ≈ $7.73 Million |
CA$-12.48 Million ≈ $-9.03 Million |
-1.167x | -91.56% |
| 2015-12-31 | CA$24.67 Million ≈ $17.85 Million |
CA$-15.03 Million ≈ $-10.88 Million |
-0.609x | +57.21% |
| 2014-12-31 | CA$13.82 Million ≈ $10.00 Million |
CA$-19.68 Million ≈ $-14.23 Million |
-1.424x | -29.41% |
| 2013-12-31 | CA$22.21 Million ≈ $16.07 Million |
CA$-24.44 Million ≈ $-17.68 Million |
-1.100x | +52.51% |
| 2012-12-31 | CA$14.79 Million ≈ $10.70 Million |
CA$-34.26 Million ≈ $-24.78 Million |
-2.317x | -203.39% |
| 2011-12-31 | CA$29.52 Million ≈ $21.35 Million |
CA$-22.54 Million ≈ $-16.31 Million |
-0.764x | -77.55% |
| 2010-12-31 | CA$41.93 Million ≈ $30.33 Million |
CA$-18.03 Million ≈ $-13.05 Million |
-0.430x | +16.02% |
| 2009-12-31 | CA$32.84 Million ≈ $23.76 Million |
CA$-16.82 Million ≈ $-12.17 Million |
-0.512x | +68.33% |
| 2008-12-31 | CA$9.45 Million ≈ $6.84 Million |
CA$-15.29 Million ≈ $-11.06 Million |
-1.617x | -233.25% |
| 2007-12-31 | CA$27.96 Million ≈ $20.23 Million |
CA$-13.57 Million ≈ $-9.82 Million |
-0.485x | -22.97% |
| 2006-12-31 | CA$30.80 Million ≈ $22.28 Million |
CA$-12.16 Million ≈ $-8.79 Million |
-0.395x | -58.73% |
| 2005-12-31 | CA$44.45 Million ≈ $32.16 Million |
CA$-11.05 Million ≈ $-8.00 Million |
-0.249x | -3.47% |
| 2004-12-31 | CA$38.39 Million ≈ $27.77 Million |
CA$-9.22 Million ≈ $-6.67 Million |
-0.240x | -9.74% |
| 2003-12-31 | CA$25.02 Million ≈ $18.10 Million |
CA$-5.48 Million ≈ $-3.96 Million |
-0.219x | +50.03% |
| 2002-12-31 | CA$16.56 Million ≈ $11.98 Million |
CA$-7.26 Million ≈ $-5.25 Million |
-0.438x | -63.61% |
| 2001-12-31 | CA$15.95 Million ≈ $11.54 Million |
CA$-4.27 Million ≈ $-3.09 Million |
-0.268x | -68.90% |
| 2000-12-31 | CA$19.92 Million ≈ $14.41 Million |
CA$-3.16 Million ≈ $-2.28 Million |
-0.159x | -105.58% |
| 1999-12-31 | CA$6.93 Million ≈ $5.01 Million |
CA$-534.35K ≈ $-386.54K |
-0.077x | -- |
About Oncolytics Biotech Inc
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative advanced and metastatic breast cancer, metastatic pancreatic ductal aden… Read more